Alimta - API Insight, 2019 - ResearchAndMarkets.com

February 1, 2019

DUBLIN--(BUSINESS WIRE)--Feb 1, 2019--The “Alimta - API Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Alimta - API Insight, 2019 provides product and API manufacturers’ details across the globe along with the location. The report gives the clear idea on the country wise DMF filed by worldwide companies related to Alimta. The report also highlights the patent details of Alimta.

Scope of the Report

A comprehensive product overview including product description, regulatory milestones, safety, pharmacological properties, clinical trials, and product development activities have been elaborated in this report Patent information around Alimta in United States (US) and Europe (EU) has been highlighted API manufacturers for Alimta in United States, Europe, China and India The report contains historical and forecasted sales for Alimta till 2021 Enlists the market competition and emerging therapies in the space where Alimta operates

Reasons to Buy

Evaluate the marketing status of Alimta to exploit opportunities for generic Alimta development opportunities Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details with respect to Alimta API intelligence over Alimta and gaining primary intelligence over Active Ingredient manufacturers by country Make more informed business decisions from insightful and in-depth analysis of Alimta’s performance

Topics Covered

1. Alimta Overview

2. Alimta Global Sales Assessment

Alimta Historical Global Sales Alimta Forecasted Global Sales

3. Product Description

Mechanism of Action Pharmacodynamic Properties Pharmacokinetic Properties

4. Product Details by Country

5. Patent Information

6. Global API Manufacturers Assessment

Active Pharmaceutical Ingredient (API) Manufacturers by Country Active Pharmaceutical Ingredient (API) Manufacturers by Region

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/7qjmf7/alimta_api?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190201005333/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Lung Cancer Drugs ,Skin Cancer Drugs



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 02/01/2019 10:37 AM/DISC: 02/01/2019 10:37 AM


Update hourly